Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3 -Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder.
about
Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.Recent advances in pharmacological management of urinary incontinence.
P2860
Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3 -Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Phase III Study to Assess Long ...... ients with Overactive Bladder.
@en
Phase III Study to Assess Long ...... ients with Overactive Bladder.
@nl
type
label
Phase III Study to Assess Long ...... ients with Overactive Bladder.
@en
Phase III Study to Assess Long ...... ients with Overactive Bladder.
@nl
prefLabel
Phase III Study to Assess Long ...... ients with Overactive Bladder.
@en
Phase III Study to Assess Long ...... ients with Overactive Bladder.
@nl
P2093
P2860
P356
P1476
Phase III Study to Assess Long ...... ients with Overactive Bladder.
@en
P2093
Osamu Yamaguchi
Sumito Ohkawa
Yasushi Ikeda
P2860
P356
10.1111/LUTS.12107
P577
2015-07-07T00:00:00Z